Bioinformatics analysis identifies AURKB as a prognostic biomarker across multiple human cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genomics

Background:

• Aurora kinase B (AURKB) plays a role in cell division and is associated with poor prognosis in certain cancers.
• Its comprehensive role across diverse cancer types remains unclear.

Purpose of the Study:

• To investigate AURKB expression, epigenetic regulation, and immune cell infiltration.
• To evaluate AURKB as a prognostic biomarker in various cancers.

Main Methods:

• Analysis of transcriptomic and clinical data from TCGA, HPA, and CCLE.
• Assessment of AURKB expression, promoter methylation, and immune infiltration using bioinformatics tools.
• Prognostic significance evaluated via Cox regression and Kaplan-Meier analysis.

Main Results:

• AURKB is overexpressed in multiple cancers (e.g., breast, liver, kidney, lung), correlating with advanced stages and poorer survival.
• Overexpression is linked to promoter hypomethylation, reduced CD8+ T cell infiltration, and chemotherapy resistance.
• AURKB demonstrates high diagnostic potential with significant Area Under the Curve values in specific cancers.

Conclusions:

• AURKB serves as a significant prognostic biomarker and potential therapeutic target due to its link with poor outcomes and chemoresistance.
• Epigenetic dysregulation and immune suppression mediated by AURKB highlight its role in the tumor microenvironment.
• Clinical integration of AURKB analysis and targeted therapies, including combination treatments, are promising for personalized cancer care.